Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paolo Vigneri

Showing results (131-140 of 150) with videos related to

Pageof 15
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2017
High <i>BCR-ABL/GUS</i> Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose ImatinibPaolo Vigneri, Fabio Stagno, Stefania Stella, et al.
Cancer Treatment Reviews|December 22, 2024
Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysisFrancesco Schettini, Sabrina Nucera, Tomás Pascual, et al.
The Journal of Clinical Investigation|April 14, 2009
Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cellsCristian Bellodi, Maria Rosa Lidonnici, Ashley Hamilton, et al.
International Journal of Molecular Sciences|May 9, 2019
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with ImatinibStefania Stella, Valentina Zammit, Silvia Rita Vitale, et al.
The Journal of Molecular Diagnostics : JMD|October 9, 2018
An Optimized Workflow to Evaluate Estrogen Receptor Gene Mutations in Small Amounts of Cell-Free DNASilvia R Vitale, Anieta M Sieuwerts, Nick Beije, et al.
Leukemia Research|June 28, 2011
Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinibRoberto Latagliata, Massimo Breccia, Fausto Castagnetti, et al.
Clinical Lung Cancer|March 1, 2021
Prospective Validation of the Italian Alliance Against Cancer Lung Panel in Patients With Advanced Non-Small-Cell Lung CancerVanesa Gregorc, Luca Mazzarella, Chiara Lazzari, et al.
Breast (Edinburgh, Scotland)|May 29, 2026
Interplay between HER2-Low status, hormone receptor expression, and therapeutic response to cyclin-dependent kinase 4/6 inhibitors as first-line treatment in luminal-like metastatic breast cancer: The CYCLHER studyLetizia Pontolillo, Elisabetta Munzone, Paolo Vigneri, et al.
Nature Communications|March 11, 2023
Recapitulating thyroid cancer histotypes through engineering embryonic stem cellsVeronica Veschi, Alice Turdo, Chiara Modica, et al.
American Journal of Hematology|May 4, 2017
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinibFausto Castagnetti, Gabriele Gugliotta, Massimo Breccia, et al.
Pageof 15

Showing results (131-140 of 150) with videos related to

Sort By:
Pageof 15
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2017
High <i>BCR-ABL/GUS</i> Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose ImatinibPaolo Vigneri, Fabio Stagno, Stefania Stella, et al.
Cancer Treatment Reviews|December 22, 2024
Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysisFrancesco Schettini, Sabrina Nucera, Tomás Pascual, et al.
The Journal of Clinical Investigation|April 14, 2009
Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cellsCristian Bellodi, Maria Rosa Lidonnici, Ashley Hamilton, et al.
International Journal of Molecular Sciences|May 9, 2019
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with ImatinibStefania Stella, Valentina Zammit, Silvia Rita Vitale, et al.
The Journal of Molecular Diagnostics : JMD|October 9, 2018
An Optimized Workflow to Evaluate Estrogen Receptor Gene Mutations in Small Amounts of Cell-Free DNASilvia R Vitale, Anieta M Sieuwerts, Nick Beije, et al.
Leukemia Research|June 28, 2011
Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinibRoberto Latagliata, Massimo Breccia, Fausto Castagnetti, et al.
Clinical Lung Cancer|March 1, 2021
Prospective Validation of the Italian Alliance Against Cancer Lung Panel in Patients With Advanced Non-Small-Cell Lung CancerVanesa Gregorc, Luca Mazzarella, Chiara Lazzari, et al.
Breast (Edinburgh, Scotland)|May 29, 2026
Interplay between HER2-Low status, hormone receptor expression, and therapeutic response to cyclin-dependent kinase 4/6 inhibitors as first-line treatment in luminal-like metastatic breast cancer: The CYCLHER studyLetizia Pontolillo, Elisabetta Munzone, Paolo Vigneri, et al.
Nature Communications|March 11, 2023
Recapitulating thyroid cancer histotypes through engineering embryonic stem cellsVeronica Veschi, Alice Turdo, Chiara Modica, et al.
American Journal of Hematology|May 4, 2017
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinibFausto Castagnetti, Gabriele Gugliotta, Massimo Breccia, et al.
Pageof 15